Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 9Terminated 3

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3CNS 1

Conditions

Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Cyclophosphamide 222pembrolizumab 201Carboplatin 173Cisplatin 168Gemcitabine 167Paclitaxel 155Docetaxel 140Bevacizumab 138Rituximab 137Radiotherapy 137Nivolumab 126Dexamethasone 126Capecitabine 103fludarabine 102Pemetrexed 92fludarabine phosphate 91Fluorouracil 91Doxorubicin 85Oxaliplatin 79Etoposide 77Cytarabine 77Bortezomib 76Erlotinib Hydrochloride 74Leucovorin 72Filgrastim 68Lenalidomide 67Calcium Dobesilate 66Irinotecan 65atezolizumab 63Radiation 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Has results × brigatinib × Clear all
NCT03737994 2026-04-23

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
10 enrolled 17 charts
Thoracic

Lung Neoplasms

NCT02706626 2023-01-26

Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors

Criterium, Inc.

Phase 2 Terminated
32 enrolled 9 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04634110 2022-10-24

Brigatinib Before Brain Irradiation Trial (B3i Trial)

University of Colorado, Denver

Phase 2 Terminated
1 enrolled 6 charts
CNSThoracic

Brain Neoplasms, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡